ASX Mkt. Sensitive<p>Argenica Therapeutics ( <a href="https://mastodon-grafa.social/tags/AGN" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>AGN</span></a> ) has released " Last Patient Dosed in Phase 2 Stroke Trial " on Fri 11 Apr at 08:21 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <br><a href="https://grafa.com/asset/argenica-therapeutics-ltd-320-agn.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=agn.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/argenica-thera</span><span class="invisible">peutics-ltd-320-agn.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=agn.asx</span></a></p>